Divi’s Labs (DIVI) Report Interpretation

Overview

Goldman Sachs reviews Divi’s Labs’ 1QFY27 earnings beat and investor concerns around Entresto concentration, GLP-1 economics, project timing, margins and valuation. It maintains a bullish view that Custom Synthesis growth, GLP-1 commercialisation and capacity investments will drive a multi-year acceleration in revenue, earnings and margins.

Core views

Divi’s reported a substantially stronger-than-expected 1QFY27, which Goldman Sachs views as validation of its upgrade thesis. Revenue rose 28% year on year to Rs30.8 billion and operating EBITDA increased 72% to Rs12.55 billion, 35% above Goldman Sachs estimates. EBITDA margin reached 40.7%, 700 basis points above Goldman Sachs expectations, as Custom Synthesis growth improved mix and operating leverage. Custom Synthesis revenue grew 45% year on year to Rs18.48 billion, 21% above estimates and representing 60% of revenue; Generic API revenue rose 6% as pricing adjustments offset higher raw-material and solvent costs. Nutraceutical revenue grew 19% year on year in the quarter. The firm raises FY27-29E EPS by 3-10% to incorporate the quarter and revised operating assumptions. It forecasts revenue growth accelerating to about a 22% CAGR in FY26-29E from 11% in FY23-26, led by a 28% Custom Synthesis CAGR. Forecast revenue rises from Rs105.6 billion in FY26 to Rs119.6 billion in FY27E, Rs142.0 billion in FY28E and Rs189.5 billion in FY29E; EPS is projected at Rs113.34, Rs139.77 and Rs202.52 for FY27E-29E. Goldman Sachs states FY29E EPS is now up to 17% above consensus. A central investor concern is the potential loss of Entresto-related sales after patent expiry in Europe and other regions in 4QCY26. Goldman Sachs acknowledges product concentration as a key risk: the top five molecules accounted for 48% of FY26 sales, while Entresto is estimated at roughly 18-20% of total revenue. Its model already assumes Entresto revenue falls from an estimated US$215 million in FY26 to US$75 million in FY27 and US$26 million in FY28. The report nevertheless argues the market overstates the immediate impact because innovator companies retain meaningful global share after patent expiry and Divi’s has long experience as a preferred low-cost partner for mature molecules. It also expects contrast media, Kisqali and the recently approved Enlicitide to partly offset the decline. Goldman Sachs identifies GLP-1 peptide-fragment supply as the larger medium-term offset. It expects commercialisation to begin in 1HFY28 and projects GLP-1 sales of US$85 million in FY28E, rising to US$1.1 billion by FY31E. Although Divi’s produces peptide fragments rather than conducting final API purification, the report regards this as a strategic, high-margin position: backward integration into Fmoc-protected amino acids gives the company control over fragment purity and can reduce customers’ purification costs. Its EXIM-data tracking indicates Divi’s has moved toward more complex fragments at commercial-scale shipments of 1,000-2,000 kg per order. The report further notes that oral GLP-1 therapies may require 10-15 times the API volume of injectables because of lower bioavailability, fitting Divi’s large-scale chemical-synthesis capability. On project timing, management has indicated that three dedicated Custom Synthesis projects will commercialise only in late CY27. Goldman Sachs does not expect a FY27 growth vacuum: it models 13% revenue growth in FY27E, accelerating to 19% in FY28E and 33% in FY29E as GLP-1 and dedicated-project volumes ramp. Validation batches and qualifications for the three projects, together with existing commercial projects, are expected to support roughly 16% Custom Synthesis growth. The firm also expects core Generic API volumes to recover as pricing pressure moderates, while nutraceuticals—up 21% to Rs9.5 billion in FY26 after capacity expansion—remain a supporting contributor. The margin thesis rests on mix and operating leverage rather than a broad-based recovery in generics alone. Goldman Sachs forecasts 650 basis points of EBITDA-margin expansion by FY29E, to 39.1% in FY29E from 32.6% in FY26. It expects Custom Synthesis to rise from 55% to 64% of revenue, with higher-margin GLP-1 and other Custom Synthesis products driving the shift. It also assumes low-teens Generic API growth after three years in which volume growth was offset by price pressure, citing signs of improved India API export prices after 12 months of weakness. Kakinada Unit 3 is now operational for starting materials and intermediates, freeing higher-value GMP capacity at Units 1 and 2 for Custom Synthesis validation and launches without immediate new GMP capex. The report addresses the premium valuation and lower fixed-asset turnover as consequences of an investment phase rather than evidence of deteriorating economics. Divi’s trades at 58x FY28E P/E, near its two-year historical average and at an approximately 40% premium to the sector, while fixed-asset turnover fell from 2.2x in FY19-23 to 1.7x in FY23-26. Goldman Sachs expects annual capex of roughly Rs26-30 billion during the forecast period following Rs25 billion in FY26, and expects turnover to improve as revenue growth accelerates in FY28E-29E. It cites an 82% historical correlation between capex and revenue two years later, three long-term supply agreements with capacity-reservation advances, a debt-free balance sheet with Rs36 billion cash, and projected FY29E ROE of 23% and CROCI of 24.3%. The firm acknowledges that conversion timing is less certain than its model implies. Goldman Sachs reiterates Buy and raises the 12-month target price to Rs9,070 from Rs8,025. The target is SOTP-based and includes an Rs742 NPV for the GLP-1 opportunity; it implies a company-level P/E of about 64x on its Q5-Q8 EPS estimates. The report argues that the expected scale and visibility of the growth cycle justify the premium valuation.

Analysis framework

Goldman Sachs starts with the quarterly earnings surprise and segment performance, then updates earnings forecasts. It tests its thesis against investor concerns by modelling Entresto erosion, assessing GLP-1 fragment economics and project timing, and linking expected Custom Synthesis mix, generic pricing and capacity use to margin outcomes. It then evaluates capex, asset turnover, balance-sheet strength and valuation before deriving an SOTP-based target price.

Methodology notes

• Valuation methodsSOTP (Sum-of-the-Parts) Valuation

  SOTP-based target price including an NPV of Rs742 for the GLP-1 opportunity

  The report values Divi’s by combining component values, explicitly including the present value assigned to the GLP-1 opportunity, to arrive at its Rs9,070 target price.

• Industry AnalysisVolume-price decomposition

  Segment growth and margin analysis separating Custom Synthesis mix, Generic API volumes and pricing

  Goldman Sachs explains earnings through segment-level volume, pricing and product-mix changes, with higher-margin Custom Synthesis growth and easing generic pricing pressure supporting margins.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Divi’s Labs (DIVI.BO)

  Primary covered company; expected to benefit from Custom Synthesis growth, GLP-1 commercialisation, improving mix and capacity utilisation.

  Strengths

  World-class chemistry capabilities, backward integration in amino acids, commercial-scale fragment shipments, debt-free balance sheet and expanding Custom Synthesis mix.

  Weaknesses

  Revenue concentration and temporarily lower fixed-asset turnover during a high-capex phase.

  Comparison

  Trades at 58x FY28E P/E, approximately 40% above the sector; Goldman Sachs cites a two-year historical-average context.

  Risks

  Top-five API concentration, USFDA compliance issues, API pricing pressure and GLP-1 commercialisation delays.

Key data

• 1QFY27 revenueRs30.8 billionUp 28% year on year and 12% above Goldman Sachs estimates.
• 1QFY27 operating EBITDARs12.55 billionUp 72% year on year and 35% above Goldman Sachs estimates.
• 1QFY27 EBITDA margin40.7%700 basis points above Goldman Sachs estimates.
• 1QFY27 Custom Synthesis revenueRs18.48 billionUp 45% year on year, 21% above estimates and 60% of revenue.
• FY27-29E EPS revision3-10% increaseFY29E EPS is now up to 17% above consensus.
• GLP-1 sales forecastUS$85 million in FY28E; US$1.1 billion in FY31ECommercialisation is expected from 1HFY28.
• FY29E EBITDA margin39.1%Goldman Sachs forecasts 650 basis points of expansion from FY26.
• 12-month target priceRs9,070Raised from Rs8,025; based on SOTP and including Rs742 NPV for GLP-1.

Impact & implications

The report argues that the 1QFY27 result strengthens the case for an earnings-growth inflection: Custom Synthesis, GLP-1 supply and capacity deployment are expected to more than offset mature-product erosion and lift margins. Its valuation case depends on execution of the commercial ramp and eventual recovery in asset productivity after the current capex cycle.

Risks

• Revenue concentration is significant: the top five molecules contributed 48% of FY26 sales, and Entresto is estimated at roughly 18-20% of total revenue.
• USFDA compliance issues could affect operations.
• API-market pricing pressure could weigh on the Generic API business and margins.
• Delays in GLP-1 commercialisation could postpone the expected growth ramp.
• Capacity and contract conversion timing is less certain than Goldman Sachs’ model implies.